About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 628 record(s)
January 2024
Req # A-2023-000098
Correspondence sent by Minister Sean Fraser to municipalities across Canada related to the Housing Accelerator Fund or zoning changes in the municipalities between July 28 to November 24, 2023Organization: Infrastructure Canada
January 2024
Req # A-2023-000101
Records detailing costs associated with personal drivers for the executive team. Include staffing costs for any drivers on-staff, or the costs of hiring them on a as-needed basis. Also include details for any vehicles purchased, or any vehicle maintenance costs. Limit time frame between 2018 and 2023Organization: Infrastructure Canada
January 2024
Req # A-2023-000105
Any report, study, briefing note or other document showing how the government produced its estimates for housing starts under the Housing Accelerator FundOrganization: Infrastructure Canada
January 2024
Req # A-2023-000106
Most up-to-date version of your department’s Code of Conduct, Values and Ethics.Organization: Infrastructure Canada
January 2024
Req # A-2017-000565
All reports or records in the custody or control of Health Canada, in any format relating to communications within Health Canada or between Health Canada and its external consultants or experts regarding the potential connection between food and beverage marketing and childhood obesity. Date Range: January 1, 2015 to July 19, 2017.Organization: Health Canada
January 2023
Req # A-2018-000773
Between January 1, 2014 to August 30, 2018: Any submissions or other correspondence received by Health Canada regarding pharmaceuticals manufacturer coupon card programs and any response issued by Health Canada to such submissions or correspondence.Organization: Health Canada
January 2023
Req # A-2018-001470
All safety reviews of Rasilez (aliskiren) or c since the products were first approved in Canada to January 18, 2019.Organization: Health Canada
January 2023
Req # A-2019-000536
All documents regarding the approval of Crest Gum Detoxify from the Licensed Natural Health Products Database.Organization: Health Canada
January 2023
Req # A-2020-000178
The patient consent forms, clinical trial protocols, and investigator brochures/information (including amendments to any of the foregoing) for the following clinical trials included in: 1. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis. 2. Title: Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy. 3. Title: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis. 4. Title: A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn’s Disease. 5. Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn’s Disease, Open Label Extension.Organization: Health Canada
January 2023